28 July 2015 - Deborah Wilkes
Archived
Pfizer has "terminated" its programme to switch the cholesterol-lowering drug Lipitor (atorvastatin) from prescription-to-OTC status in the US. Chief executive officer Ian Read said the company "continues to evaluate other products for potential prescription-to-OTC switches".
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.